title: Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.
abstract: More than 15 years ago, the first generation of genetically engineered mouse (GEM) models of prostate cancer was introduced. These transgenic models utilized prostate-specific promoters to express SV40 oncogenes specifically in prostate epithelium. Since the description of these initial models, there have been a plethora of GEM models of prostate cancer representing various perturbations of oncogenes or tumor suppressors, either alone or in combination. This review describes these GEM models, focusing on their relevance for human prostate cancer and highlighting their strengths and limitations, as well as opportunities for the future.
authors.affiliation: Herbert Irving Comprehensive Cancer Center, Departments of Urology and Pathology & Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: Shazia
authors.initials: S
authors.lastname: Irshad
authors.forename: Cory
authors.initials: C
authors.lastname: Abate-Shen
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D016147:Genes, Tumor Suppressor; D006801:Humans; D008297:Male; D051379:Mice / Q000235:genetics*; D008822:Mice, Transgenic; D009362:Neoplasm Metastasis; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism; D011230:Precancerous Conditions; D011471:Prostatic Neoplasms / Q000209:etiology* / Q000473:pathology*; D011519:Proto-Oncogenes; D015398:Signal Transduction
chemical_list: D051059:PTEN Phosphohydrolase